Longeveron Inc. (LGVN) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates declining revenue, increased expenses, and a significant net loss, all of which are negative financial indicators. The Q&A reveals management's uncertainty in monetizing PRVs and dependence on strategic partnerships, which are risky. Despite some positive developments in manufacturing and potential partnerships, the overall financial health is concerning. The lack of clear guidance and reliance on future approvals adds to the negative sentiment. Given these factors and the absence of a market cap to gauge volatility, a strong negative stock price movement is likely.
Key Financial Performance
Revenue for 2025 $1.2 million, a decrease of $1.2 million or 50% year-over-year. The decline was due to lower participant demand for the Bahamas registry trial and reduced demand for contract manufacturing services from third-party clients.
General and Administrative Expenses for 2025 $12 million, an increase of $1.8 million or 17% year-over-year. The increase was primarily due to higher personnel and related costs, including a one-time accrued severance cost for the former CEO.
Research and Development Expenses for 2025 $12 million, an increase of $3.9 million or 48% year-over-year. The increase was driven by a $2.2 million rise in personnel and related costs, a $1.4 million increase in CMC costs associated with technology transfer, and a $0.2 million increase in amortization expense related to patent costs.
Net Loss for 2025 $22.7 million, an increase of $6.7 million or 41% year-over-year. The increase was attributed to higher general and administrative expenses and research and development costs.
Cash and Cash Equivalents as of December 31, 2025 $4.7 million, with approximately $1.4 million in working capital. Additionally, a private placement raised gross proceeds of approximately $15.9 million, extending the financial runway into the fourth quarter of 2026.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Laromestrocel for HLHS: Phase IIb clinical trial (ELPIS II) nearing completion with results expected in Q3 2026. Potential for first Biologic License Application (BLA) submission targeting a serious pediatric condition.
Laromestrocel for PDCM: IND application effective in July 2025. Planning for a pivotal Phase II trial in 2026, with potential initiation in 2027.
Strategic Partnerships: Plans to pursue partnerships for HLHS, Alzheimer's, and PDCM programs to accelerate market entry and leverage resources.
Priority Review Vouchers (PRVs): HLHS program eligible for PRV upon BLA approval, with potential financial gains from selling PRVs valued between $150M-$205M.
Financial Resources: Secured $15M in new capital with potential for an additional $15M upon meeting milestones. Runway extended into Q4 2026.
Revenue Decline: 2025 revenues decreased by 50% to $1.2M due to lower demand for Bahamas registry trial and contract manufacturing services.
Increased Expenses: General and administrative expenses rose by 17% to $12M, and R&D expenses increased by 48% to $12M, driven by personnel costs and BLA-enabling efforts.
Focus on Stem Cell Therapies: Positioning as a leader in stem cell research with multiple clinical trials and publications in premier journals.
Regulatory Pathway: Advancing towards BLA submissions for HLHS and PDCM, targeting rare pediatric diseases with unmet medical needs.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Financial Sustainability: The company reported a significant net loss of $22.7 million in 2025, a 41% increase from the previous year. This raises concerns about financial sustainability and the ability to fund operations beyond the fourth quarter of 2026 without additional capital.
Revenue Decline: Revenues decreased by 50% in 2025 compared to 2024, primarily due to lower participant demand for the Bahamas registry trial and reduced demand for contract manufacturing services. This decline could impact the company's financial health and operational capabilities.
Increased Expenses: General and administrative expenses increased by 17%, and research and development expenses rose by 48% in 2025. These rising costs, including personnel and severance expenses, could strain financial resources.
Regulatory and Clinical Risks: The success of the company's programs, including HLHS and PDCM, depends on favorable clinical trial outcomes and regulatory approvals. Any delays or negative results could significantly impact strategic objectives and financial performance.
Dependence on Strategic Partnerships: The company plans to rely on strategic partnerships for commercialization and funding. Failure to secure these partnerships could delay market entry and strain resources.
Market and Competitive Pressures: The company operates in a highly competitive stem cell therapy market. Advancements by competitors or changes in market dynamics could affect Longeveron's market position and revenue potential.
Uncertain Priority Review Voucher (PRV) Outcomes: The financial benefits from PRVs are contingent on regulatory approvals and successful sales. Any setbacks in these areas could impact anticipated financial gains.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Capital Allocation and Financial Resources: Secured $15 million in new capital with potential for an additional $15 million upon meeting milestones. Current funding expected to support operations into Q4 2026.
HLHS Program: Phase IIb ELPIS II trial results expected in Q3 2026. If data supports, preparation for a Biologic License Application (BLA) will begin. Potential for Priority Review Voucher (PRV) upon FDA approval.
Alzheimer's Disease Program: Plans to leverage Phase II data and clinical pathway clarity to engage with funding and commercialization partners.
Pediatric Dilated Cardiomyopathy (PDCM) Program: Planning and preparation for a pivotal Phase II registrational study in 2026, with potential initiation in 2027. Potential for PRV upon FDA approval.
Strategic Partnerships: Plans to pursue partnerships post-ELPIS II trial results for HLHS and based on Phase II data for Alzheimer's disease. Partnerships aimed at accelerating market entry and leveraging resources.
Stem Cell Therapy Market: Continued focus on advancing stem cell therapies, with potential transformative impact on treating serious diseases with unmet medical needs.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the commercial perspectives for scaled-up manufacturing and CMC for laromestrocel if approved for the HLHS indication?
A:The company has made significant progress in manufacturing and CMC. They are engaged with a CDMO for manufacturing, which will free up their laboratory space for other projects. Manufacturing and CMC are priorities for this year.
Q:Which potential areas of inquiry for laromestrocel could be eligible for PRVs beyond HLHS?
A:The company could seek a separate PRV for PDCM. They have sold half of one PRV to investors, while the other half and the PDCM PRV are retained by the company.
Q:What potential non-dilutive sources of capital could fund initiatives for indications like Alzheimer's disease and age-related frailty?
A:The company plans to seek licensing partners for both Alzheimer's disease and age-related frailty. Preliminary conversations have been set up, and there is incoming interest in licensing the technology. These initiatives are priorities for 2026.
Q:When can the company file for BLA for the HLHS program if the data is positive in Q3 2026? Will it be a rolling submission, and is priority review expected?
A:Assuming positive data in Q3 2026, the company plans to target BLA submission in 2027. They are eligible for rolling submission and priority review due to rare pediatric disease designation. The timing will depend on an end-of-phase meeting with the FDA.
Q:Do you expect challenges in monetizing PRVs given the new sunset date of September 2029?
A:The company expects PRV prices to remain strong, as recent sales have been in the $200 million range. However, predicting future prices is challenging.
Q:What are the next steps for the PDCM program, and what is the unmet need being addressed?
A:The company aims to initiate the PDCM trial in 2027 after feasibility assessments. The trial will include 70 patients globally, with endpoints like reduced heart transplants and hospitalizations. The unmet need is to potentially cure or reverse pediatric dilated cardiomyopathy, which currently has no curative treatments.
Q:What is the strategy for the recently patented use of laromestrocel in female sexual dysfunction?
A:The company sees this as a high unmet need and plans to pursue partnerships for development. The indication arose from aging frailty work and targets older females. A formal regulatory pathway with the FDA would be needed.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer regarding the potential challenges in monetizing PRVs given the new sunset date of September 2029. They stated it is hard to predict future prices but expect them to remain strong based on recent trends.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
BLA Alzheimer
BLA FDA
BLA commercialization
CEO Research
CEO focus
Capital Janus
Chief Science
Co Founder
Coastland Capital
ELPIS II
Enrollment
Executive Chairman
Financial Results
Founder Chief
II trial
IND
Janus Henderson
Nataliya afternoon
Officer Co
Officer Executive
PDCM
PRVs
Phase II
Revenues trial
Science Officer
advancement
commercialization partner
contract manufacturing
design ELPIS
disease need
investor
placement
proceeds
result ELPIS
role
sale HLHS
today Longeveron
trial contract
trial result
LGVN Transcript
Longeveron Inc. (LGVN) Q4 2025 Earnings Call Transcript
Unknown3-17
The earnings call summary indicates declining revenue, increased expenses, and a significant net loss, all of which are negative financial indicators. The Q&A reveals management's uncertainty in monetizing PRVs and dependence on strategic partnerships, which are risky. Despite some positive developments in manufacturing and potential partnerships, the overall financial health is concerning. The lack of clear guidance and reliance on future approvals adds to the negative sentiment. Given these factors and the absence of a market cap to gauge volatility, a strong negative stock price movement is likely.
Longeveron Inc. (LGVN) Q3 2025 Earnings Call Transcript
Unknown11-4
The earnings call reveals several concerns: increasing expenses and net loss, a postponed BLA submission, and vague management responses in the Q&A. Despite potential partnerships and strategic plans, the financial health and uncertainties around funding and timelines overshadow positive aspects. The increase in research and development expenses and the net loss, coupled with the postponed BLA submission, contribute to a negative outlook. The lack of clear guidance and specific plans to expedite regulatory processes further dampens sentiment, leading to a prediction of a negative stock price movement.
Longeveron Inc. (LGVN) Q2 2025 Earnings Call Transcript
Unknown8-13
The earnings call summary indicates a decrease in revenue and increased expenses, leading to a higher net loss. The Q&A section reveals uncertainties in pricing strategies and potential market risks. Although there are positive regulatory milestones and strategic initiatives, the financial challenges and lack of clear guidance on pricing strategies suggest a negative sentiment. Additionally, the public offering and the need for further funding introduce concerns about financial health. Overall, these factors contribute to a negative outlook for the stock price over the next two weeks.
Longeveron Inc. (LGVN) Q1 2025 Earnings Call Transcript
Unknown5-9
The earnings call presents a mixed picture: strong revenue growth in 2024 and reduced net loss, but Q1 2025 shows declining revenue and increased losses. The company's strategic priorities, such as the HLHS program and Alzheimer's initiatives, are promising, but financial and market demand risks are concerning. The Q&A section reveals some uncertainties, especially regarding patient enrollment and manufacturing scale-up. The absence of a shareholder return plan or guidance adjustments adds to the neutral sentiment. Overall, the stock is likely to remain stable, with no strong catalysts for significant movement.
LGVN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
